日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

The Parasite Reduction Ratio (PRR) Assay Version 2: Standardized Assessment of Plasmodium falciparum Viability after Antimalarial Treatment In Vitro

寄生虫减少率(PRR)检测方法第二版:体外抗疟治疗后恶性疟原虫存活率的标准化评估

Walz, Annabelle; Duffey, Maëlle; Aljayyoussi, Ghaith; Sax, Sibylle; Leroy, Didier; Besson, Dominique; Burrows, Jeremy N; Cherkaoui-Rbati, Mohammed H; Gobeau, Nathalie; Westwood, Marie-Anne; Siethoff, Christoph; Gamo, Francisco-Javier; Mäser, Pascal; Wittlin, Sergio

A pharmacokinetic-pharmacodynamic model for chemoprotective agents against malaria

抗疟化学保护剂的药代动力学-药效学模型

Mohammed H Cherkaoui-Rbati, Nicole Andenmatten, Lydia Burgert, Oluwaseun F Egbelowo, Rolf Fendel, Chiara Fornari, Michael Gabel, John Ward, Jörg J Möhrle, Nathalie Gobeau

New In Vitro Interaction-Parasite Reduction Ratio Assay for Early Derisk in Clinical Development of Antimalarial Combinations

用于早期降低抗疟药物组合临床开发风险的新型体外相互作用-寄生虫减少率检测方法

Wicha, Sebastian G; Walz, Annabelle; Cherkaoui-Rbati, Mohammed H; Bundgaard, Nils; Kuritz, Karsten; Gumpp, Christin; Gobeau, Nathalie; Möhrle, Jörg; Rottmann, Matthias; Demarta-Gatsi, Claudia

Parasite Viability as a Measure of In Vivo Drug Activity in Preclinical and Early Clinical Antimalarial Drug Assessment

寄生虫生存力作为临床前和早期临床抗疟药物评估中体内药物活性的衡量标准

Georges F R Radohery #, Annabelle Walz #, Christin Gumpp, Mohammed H Cherkaoui-Rbati, Nathalie Gobeau, Jeremy Gower, Miles P Davenport, Matthias Rottmann, James S McCarthy, Jörg J Möhrle, Maria Rebelo, Claudia Demarta-Gatsi, David S Khoury

The antimalarial MMV688533 provides potential for single-dose cures with a high barrier to Plasmodium falciparum parasite resistance

抗疟药MMV688533具有单剂量治愈的潜力,且对恶性疟原虫的耐药性具有很高的屏障。

James M Murithi,Cécile Pascal,Jade Bath,Xavier Boulenc,Nina F Gnädig,Charisse Flerida A Pasaje,Kelly Rubiano,Tomas Yeo,Sachel Mok,Sylvie Klieber,Paul Desert,María Belén Jiménez-Díaz,Jutta Marfurt,Mélanie Rouillier,Mohammed H Cherkaoui-Rbati,Nathalie Gobeau,Sergio Wittlin,Anne-Catrin Uhlemann,Ric N Price,Grennady Wirjanata,Rintis Noviyanti,Patrick Tumwebaze,Roland A Cooper,Philip J Rosenthal,Laura M Sanz,Francisco Javier Gamo,Jayan Joseph,Shivendra Singh,Sridevi Bashyam,Jean Michel Augereau,Elie Giraud,Tanguy Bozec,Thierry Vermat,Gilles Tuffal,Jean-Michel Guillon,Jérôme Menegotto,Laurent Sallé,Guillaume Louit,Marie-José Cabanis,Marie Françoise Nicolas,Michel Doubovetzky,Rita Merino,Nadir Bessila,Iñigo Angulo-Barturen,Delphine Baud,Lidiya Bebrevska,Fanny Escudié,Jacquin C Niles,Benjamin Blasco,Simon Campbell,Gilles Courtemanche,Laurent Fraisse,Alain Pellet,David A Fidock,Didier Leroy

A randomized, double-blind, phase 2b study to investigate the efficacy, safety, tolerability and pharmacokinetics of a single-dose regimen of ferroquine with artefenomel in adults and children with uncomplicated Plasmodium falciparum malaria

一项随机、双盲、2b期研究,旨在探讨单剂量氟喹诺酮联合阿特芬诺美治疗成人和儿童单纯性恶性疟疾的疗效、安全性、耐受性和药代动力学。

Adoke, Yeka; Zoleko-Manego, Rella; Ouoba, Serge; Tiono, Alfred B; Kaguthi, Grace; Bonzela, Juvêncio Eduardo; Duong, Tran Thanh; Nahum, Alain; Bouyou-Akotet, Marielle; Ogutu, Bernhards; Ouedraogo, Alphonse; Macintyre, Fiona; Jessel, Andreas; Laurijssens, Bart; Cherkaoui-Rbati, Mohammed H; Cantalloube, Cathy; Marrast, Anne Claire; Bejuit, Raphaël; White, David; Wells, Timothy N C; Wartha, Florian; Leroy, Didier; Kibuuka, Afizi; Mombo-Ngoma, Ghyslain; Ouattara, Daouda; Mugenya, Irène; Phuc, Bui Quang; Bohissou, Francis; Mawili-Mboumba, Denise P; Olewe, Fredrick; Soulama, Issiaka; Tinto, Halidou

Chemoprotective Antimalarial Activity of P218 against Plasmodium falciparum: A Randomized, Placebo-Controlled Volunteer Infection Study

P218 对恶性疟原虫的化学保护性抗疟活性:一项随机、安慰剂对照的志愿者感染研究

Chughlay, Mohamed Farouk; El Gaaloul, Myriam; Donini, Cristina; Campo, Brice; Berghmans, Pieter-Jan; Lucardie, Alexander; Marx, Michael W; Cherkaoui-Rbati, Mohammed H; Langdon, Grant; Angulo-Barturen, Iñigo; Viera, Sara; Rosanas-Urgell, Anna; Van Geertruyden, Jean-Pierre; Chalon, Stephan

A Phase 1, Placebo-controlled, Randomized, Single Ascending Dose Study and a Volunteer Infection Study to Characterize the Safety, Pharmacokinetics, and Antimalarial Activity of the Plasmodium Phosphatidylinositol 4-Kinase Inhibitor MMV390048

一项 1 期安慰剂对照、随机、单次递增剂量研究和一项志愿者感染研究,旨在表征疟原虫磷脂酰肌醇 4-激酶抑制剂 MMV390048 的安全性、药代动力学和抗疟活性。

McCarthy, James S; Donini, Cristina; Chalon, Stephan; Woodford, John; Marquart, Louise; Collins, Katharine A; Rozenberg, Felix D; Fidock, David A; Cherkaoui-Rbati, Mohammed H; Gobeau, Nathalie; Möhrle, Jörg J